Cardiac troponin I but not n-terminal pro-b-type natriuretic peptide predicts outcomes in cardiogenic shock

• Verfasst von: Schupp, Tobias [VerfasserIn]
• Verfasst von: Rusnak, Jonas [VerfasserIn]
• Verfasst von: Forner, Jan [VerfasserIn]
• Verfasst von: Weidner, Kathrin [VerfasserIn]
• Verfasst von: Ruka, Marinela [VerfasserIn]
• Verfasst von: Egner-Walter, Sascha [VerfasserIn]
• Verfasst von: Dudda, Jonas [VerfasserIn]
• Verfasst von: Bertsch, Thomas [VerfasserIn]
• Verfasst von: Kittel, Maximilian [VerfasserIn]
• Verfasst von: Behnes, Michael [VerfasserIn]
• Verfasst von: Akın, Ibrahim [VerfasserIn]
• Titel: Cardiac troponin I but not n-terminal pro-b-type natriuretic peptide predicts outcomes in cardiogenic shock
• Verf.angabe: Tobias Schupp, Jonas Rusnak, Jan Forner, Kathrin Weidner, Marinela Ruka, Sascha Egner-Walter, Jonas Dudda, Thomas Bertsch, Maximilian Kittel, Michael Behnes and Ibrahim Akin
• Jahr: 2023
• Umfang: 17 S.
• Illustrationen: Illustrationen
• Fussnoten: Veröffentlicht: 31. August 2023 ; Gesehen am 27.10.2023
• Titel Quelle: Enthalten in: Journal of Personalized Medicine
• Ort Quelle: Basel : MDPI, 2011
• Jahr Quelle: 2023
• Band/Heft Quelle: 13(2023), 9, Artikel-ID 1348, Seite 1-17
• ISSN Quelle: 2075-4426
• DOI: doi:10.3390/jpm13091348
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: biomarkers
• Sach-SW: cardiac troponin I
• Sach-SW: cardiogenic shock
• Sach-SW: mortality
• Sach-SW: NT-proBNP
• Sach-SW: prognosis
• K10plus-PPN: 1868574628

Abstract

This study investigates the prognostic value of cardiac troponin I (cTNI) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in patients with cardiogenic shock (CS). Data regarding the prognostic value of cardiac biomarkers in CS is scarce, furthermore, most studies were restricted to CS patients with acute myocardial infarction (AMI). Therefore, consecutive patients with CS from 2019 to 2021 were included. Blood samples were retrieved from day of disease onset (day 1) and on days 2, 3 and 4 thereafter. The prognostic value of cTNI and NT-proBNP levels was tested for 30-day all-cause mortality. Statistical analyses included univariable t-tests, Spearman’s correlations, Kaplan-Meier analyses and multivariable Cox proportional regression analyses. A total of 217 CS patients were included with an overall rate of all-cause mortality of 56% at 30 days. CTNI was able to discriminate 30-day non-survivors (area under the curve (AUC) = 0.669; p = 0.001), whereas NT-proBNP (AUC = 0.585; p = 0.152) was not. The risk of 30-day all-cause mortality was higher in patients with cTNI levels above the median (70% vs. 43%; log rank p = 0.001; HR = 2.175; 95% CI 1.510-3.132; p = 0.001), which was observed both in patients with (71% vs. 49%; log rank p = 0.012) and without AMI-related CS (69% vs. 40%; log rank p = 0.005). The prognostic impact of cTNI was confirmed after multivariable adjustment (HR = 1.915; 95% CI 1.298-2.824; p = 0.001). In conclusion, cTNI—but not NT-proBNP—levels discriminated 30-day all-cause mortality in CS patients.